Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Nontuberculosis mycobacteria (NTM) infection of cochlear implants are exceedingly rare. Here, we report one such case and review the literature surrounding previous reports. Case report. A 76-year-old female underwent right cochlear implantation. Her course was complicated by wound dehiscence, three surgical debridements, and ultimately explantation. Cultures ultimately grew , which was effectively treated with Azithromycin, Omadacycline, and 3 months of injectable Cefoxitin. At the latest follow-up, the patient is without evidence of further infection and pending reimplantation. NTM is a rare cause of postsurgical infections following cochlear implantation. It is especially important to consider this in cases of indolent, antibiotic-resistant infections to optimize patient treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12058316 | PMC |
| http://dx.doi.org/10.1155/crot/5973005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recessive variants in TWNK cause syndromic and non-syndromic post-synaptic auditory neuropathy through MtDNA replication defects.
Hum Genet
September 2025
College of Otolaryngology Head and Neck Surgery, Chinese PLA General Hospital, Chinese PLA Medical School, 28 Fuxing Road, Beijing, 100853, China.
Recessive variants in TWNK cause syndromes arising from mitochondrial DNA (mtDNA) depletion. Hearing loss is the most prevalent manifestation in individuals with these disorders. However, the clinical and pathophysiological features have not been fully elucidated.
View Article and Find Full Text PDFThe Green Cochlea.
Braz J Otorhinolaryngol
September 2025
Clinical Research Department, MED-EL GmbH, Innsbruck, Austria.
Objectives: Healthcare systems contribute significantly to global greenhouse gas emissions through energy consumption and waste generation. This study aims to explore strategies to make cochlear implantation processes more environmentally sustainable and aligned with the United Nations' Sustainable Development Goals.
Methods: We examined various approaches including the use of bio-based and biodegradable materials, sustainable energy solutions, greener anesthetic practices, effective waste separation and recycling in operating rooms, and patient-centered strategies such as reducing travel and promoting early activation and fitting of cochlear implants.
Management of Unilateral Hearing Loss in a 14-Year-Old with Internal Auditory Canal Duplication Using a Bonebridge Bone Conduction Implant.
Am J Case Rep
September 2025
Oto-Rhino-Laryngology Surgery Clinic, Institute of Physiology and Pathology of Hearing - World Hearing Center, Kajetany, Poland.
BACKGROUND Duplicated internal auditory canal (dIAC) is a rare congenital temporal bone anomaly associated with ipsilateral sensorineural hearing loss (SNHL). The Bonebridge bone conduction implant has a magnet, an internal transducer, and an external audio processor. This report is of a 14-year-old girl with unilateral SNHL and vestibulocochlear nerve (VIII cranial nerve) aplasia due to dIAC who was treated with a Bonebridge bone conduction implant.
View Article and Find Full Text PDFObjective: This study aims to evaluate long-term auditory outcomes in patients with inner ear malformations (IEMs) treated with cochlear or auditory brainstem implants (CI/ABI), and to assess the influence of anatomical subtype, electrode design, insertion depth, and genetic/syndromic background on hearing performance over a 10-year follow-up.
Methods: We conducted a prospective cohort study including patients with radiologically confirmed IEMs and bilateral severe-to-profound hearing loss, all of whom underwent implantation and completed at least 10 years of follow-up. Outcomes were assessed using pure-tone average (PTA) and speech recognition scores (SRS) at defined intervals.
Gene therapy for inner ear disease: the next targets.
Curr Opin Otolaryngol Head Neck Surg
October 2025
Department of Otolaryngology Head and Neck Surgery, University of Vienna, Vienna, Austria.
Purpose Of Review: The recent successful otoferlin gene therapy trials have refocused the fields attention on the potential of gene therapy to cure hearing loss. With over 100 known monogenetic causes of hearing loss, the key question is which will be the next set of disorders that are treatable. The current review addresses potentially targetable hearing disorders that can be addressed with current gene therapy technologies.
View Article and Find Full Text PDF